Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Gedatolisib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Celcuity Publishes Phase 3 Gedatolisib Study Results
    Celcuity Publishes Phase 3 Gedatolisib Study Results

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3252366/0/en/Celcuity-Announces-Publication-of-Results-from-PIK3CA-Wild-Type-Cohort-of-Phase-3-VIKTORIA-1-Study-of-Gedatolisib-Regimens-in-HR-HER2-Advanced-Breast-Cancer-in-Journal-of-Clinical-.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    FDA Accepts Celcuity's Gedatolisib for HR+/HER2- PIK3CA-WT Cancer
    FDA Accepts Celcuity's Gedatolisib for HR+/HER2- PIK3CA-WT Cancer

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221601/0/en/Celcuity-Announces-FDA-Acceptance-of-New-Drug-Application-for-Gedatolisib-in-HR-HER2-PIK3CA-Wild-Type-Advanced-Breast-Cancer.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Celcuity Presents PIK3CA WT VIKTORIA-1 Results at 2025 SABCS
    Celcuity Presents PIK3CA WT VIKTORIA-1 Results at 2025 SABCS

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3204248/0/en/Celcuity-Presents-Updated-Results-from-the-PIK3CA-Wild-Type-Cohort-of-the-Phase-3-VIKTORIA-1-Trial-at-the-2025-San-Antonio-Breast-Cancer-Symposium.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Celcuity to Present Updated VIKTORIA-1 Data at SABCS 2025
    Celcuity to Present Updated VIKTORIA-1 Data at SABCS 2025

    26 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/26/3195381/0/en/Celcuity-to-Present-Updated-Data-from-the-PIK3CA-Wild-Type-Cohort-of-the-Phase-3-VIKTORIA-1-Trial-at-the-2025-San-Antonio-Breast-Cancer-Symposium.html

    GLOBENEWSWIRE
    26 Nov 2025
    Share Share
    Celcuity Submits NDA for Gedatolisib in HR+/HER2- Breast Cancer
    Celcuity Submits NDA for Gedatolisib in HR+/HER2- Breast Cancer

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3189580/0/en/Celcuity-Announces-Completion-of-Submission-of-Its-New-Drug-Application-to-the-U-S-FDA-for-Gedatolisib-in-HR-HER2-PIK3CA-Wild-Type-Advanced-Breast-Cancer.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share
    Celcuity Reports Q3 2025 Financial Results & Corporate Update
    Celcuity Reports Q3 2025 Financial Results & Corporate Update

    12 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/12/3186736/0/en/Celcuity-Inc-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    12 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.